Catalog #CP153

RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG)

Clone RMP1-14-CP153
Reactivities Mouse
Product Citations 1
Isotype Mouse IgG2a, κ

$235.00 - $6,391.00

$235.00 - $6.00

Choose an Option...
  • 100 mg - $6,391.00
  • 50 mg - $4,574.00
  • 25 mg - $3,182.00
  • 5 mg - $911.00
  • 1 mg - $235.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Description

The RMP1-14-CP153 monoclonal antibody is a chimeric version of the original RMP1-14 antibody. The variable domain sequences are identical to the original RMP1-14 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. The RMP1-14-CP153 antibody also contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. RMP1-14-CP153 reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments.

Specifications

Isotype Mouse IgG2a, κ
Recommended Isotype Control(s) RecombiMAb mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Mutations LALA-PG
Immunogen Syrian Hamster BKH cells transfected with mouse PD-1 cDNA
Reported Applications in vivo blocking of PD-1/PD-L signaling*
*Reported for the original rat IgG2a RMP1-14 antibody
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <1EU/mg (<0.001EU/μg)
Determined by LAL gel clotting assay
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from CHO cell supernatant in an animal free facility
Purification Protein G
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options

Product Citations

  • Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy.

    In J Immunother Cancer on 2 May 2025 by Poppe, L. K., Roller, N., et al.

    PubMed

    Human papillomavirus (HPV)-associated malignancies continue to present a major health concern despite the development of prophylactic vaccines. Standard therapies offer limited benefit to patients with advanced-stage disease. Despite improved outcomes with programmed cell death protein-1 (PD-1) targeted therapies, treatment resistance and modest response rates highlight a significant unmet need to develop novel therapies for these patients. PDS0101 (designated HPV vaccine) is a liposomal nanoparticle HPV16-specific therapeutic vaccine that has been shown to generate strong HPV-specific responses in preclinical and clinical studies. Here we assess the efficacy of this HPV vaccine in combination with the tumor-targeting immunocytokine NHS-IL12 (PDS01ADC), plus either αPD-1 or the class I histone deacetylase inhibitor Entinostat.

View More

Product FAQs

Related Products

  1. Catalog #CP162
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  2. Catalog #CP157
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  3. Catalog #CP151
    RecombiMAb anti-mouse PD-1 (CD279) (D265A) Read more
  4. Catalog #SIM0010
    InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) Read more
  5. Catalog #SIM0003
    InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) Read more
  6. Catalog #BP0273
    InVivoPlus anti-mouse PD-1 (CD279) Read more
  7. Catalog #BE0273
    InVivoMAb anti-mouse PD-1 (CD279) Read more
  8. Catalog #BP0146
    InVivoPlus anti-mouse PD-1 (CD279) Read more
  9. Catalog #BP0033-2
    InVivoPlus anti-mouse PD-1 (CD279) Read more
  10. Catalog #BE0146
    InVivoMAb anti-mouse PD-1 (CD279) Read more
  11. Catalog #BE0033-2
    InVivoMAb anti-mouse PD-1 (CD279) Read more
  12. Catalog #BE0193
    InVivoMAb anti-human PD-1 (CD279) Read more
  13. Catalog #BE0188
    InVivoMAb anti-human PD-1 (CD279) Read more
  14. Catalog #CP159
    RecombiMAb anti-mouse PD-1 (CD279) Read more

Additional Formats

  1. Catalog #BE0146
    InVivoMAb anti-mouse PD-1 (CD279) Read more
  2. Catalog #BP0146
    InVivoPlus anti-mouse PD-1 (CD279) Read more
  3. Catalog #CP151
    RecombiMAb anti-mouse PD-1 (CD279) (D265A) Read more
  4. Catalog #CP157
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  5. Catalog #CP162
    RecombiMAb anti-mouse PD-1 (CD279) Read more